|Articles|November 25, 2008

FDA Definition of Whole Grains Limits Support for Heart Disease Claims

A new study by the Life Science Research Office announced on November 24, found that “The FDA definition for whole grains as a selection criterion to evaluate the scientific literature is limiting because most of the studies use a broader concept of whole grains.”

BETHESDA, MD (November, 2008) – Since 2005, FDA has allowed manufacturers to make health claims tying heart disease reduction to a diet rich in whole grains. Yet it was not until 2006 that FDA defined whole grains as the “the intact, ground, cracked or flaked fruit of the grains whose principal components-the starchy endosperm, germ and bran-…present in the same relative proportions as they exist in the intact grain.”

A new study by the Life Science Research Office announced on November 24, found that:

•“The FDA definition for whole grains as a selection criterion to evaluate the scientific literature is limiting because most of the studies use a broader concept of whole grains.

•The few studies that meet the FDA whole grains definition provide insufficient scientific evidence to support a CVD health claim.

•A whole grains and CVD health claim is supported when a larger number of studies that use a broader concept of whole grain that includes isolated bran, germ or fiber in their analysis of whole grains are also considered.

•The scientific evidence on risk reduction of diabetes and whole grain consumption is suggestive, but not conclusive, whether or not the study meets the FDA definition of whole grains.

•This type of analysis is complicated by the diversity in nutrients and bioactive components of different types of whole grains. “


The results of the study are part of an LSRO report titled, “Whole Grain Intake and Cardiovascular Disease and Whole Grain Intake and Diabetes: A Review.”


Related to this article

SupplySide Global Vitaquest
Live from SupplySide Global 2026, Nutritional Outlook’s Nicholas Jacobus speaks with Michael Anthonavage, VP of innovation at Vitaquest International, about the company’s 2027 consumer trends forecast and how it’s shaping supplement formulation.
Laurentia Bliss
Live from SupplySide Global 2026, Laurentia Bliss talks about new athlete-focused research on Magtein, ThreoTech’s brain-targeted magnesium ingredient, and upcoming innovations like effervescent tablets and gummies.
Klaus Neumann
Live from SupplySide Global 2026, Klaus Neumann talks about Concordix's chewable supplement line spanning beauty and gut-immune health, including BeautyBioti, a Skin & Hair Vitality Complex, and FortiBiotic.